AST 201 - Aptamer Sciences
Alternative Names: AST 201 Aptamer drug conjugate; AST-201 ApDC; AST201 - Aptamer SciencesLatest Information Update: 15 Apr 2024
At a glance
- Originator Aptamer Sciences
- Class Amines; Antineoplastics; Cancer vaccines; Deoxyribonucleosides; DNA vaccines; Drug conjugates; Ketones; Pyrimidine nucleosides; Pyrimidines; Vaccines
- Mechanism of Action Cytidine deaminase inhibitors; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in South Korea (unspecified route) prior to April 2024 (Aptamer Sciences pipeline, April 2024)
- 27 Mar 2024 Aptamer Sciences plans a phase I trial for Solid tumours in South Korea
- 12 Mar 2024 Aptamer Sciences files an IND application with the Korean Ministry of Food and Drug Safety in South Korea for Solid tumours